Mindray is expanding its biomarker portfolio for cardiology to enable state-of-the-art hs-cTnI care for cardiovascular diseases

2023-10-23 16:14:35

Shenzhen, China (ots/PRNewswire) – Mindray (SZSE: 300760), a global leader in medical devices and solutions, introduces high-sensitivity troponin I (hs-cTnI) and NT-proBNP as cardiac biomarkers. The new additions expand Mindray’s diverse portfolio of cardiac biomarkers for the diagnosis and management of cardiovascular disease (CVD).

Since cardiovascular disease is the leading cause of death worldwide, early detection is the key to saving lives. The guidelines recommend the use of cTnl and NT-proBNP as essential biomarkers in suspected acute coronary syndrome (ACS) and heart failure for early screening, risk stratification, rapid diagnosis and therapeutic monitoring.

The two assays are the result of a collaboration between Mindray and HyTest, a Mindray company and a global leader in antibodies and antigens. HyTest is known for its expertise in cardiac biomarkers. Its cardiac troponin complex material was selected by the AACC as the international troponin standard in 2004.

Both tests have been validated by the Wuhan Asian Heart Hospital in China and the Hennepin Healthcare Research Institute in the USA and demonstrate excellent clinical performance.

Mindray hs-cTnI assay: reliable detection of myocardial damage with a high detection rate and low CV

Mindray’s hs-cTnI assay far exceeds the minimum requirements for hs-cTn, achieving a remarkable 93% detection rate between LoD and the 99th URL and an imprecision CV of less than 5% at the 99th URL. This demonstrates the test’s exceptional sensitivity, precision and reliability in detecting heart muscle damage. Additionally, a 0-2h study of the diagnostic algorithm conducted at the Hennepin Healthcare Research Institute supports its effectiveness in diagnosing and treating heart disease within this crucial time period.

Mindray NT-proBNP assay with high precision and strong anti-interference capacity

NT-proBNP is an established cardiac marker for heart failure and its treatment. Mindray’s NT-proBNP assay has high precision with a CV of ≤5% and effectively minimizes interference from 55 common heart disease drugs, demonstrating its reliability in the detection and treatment of heart failure.

“By integrating HyTest’s breakthrough antibodies and cardiac biomarker research with Mindray’s advanced reagent technology and platform, we will deliver more reliable solutions that will lead to improved patient outcomes in the area of cardiovascular disease and beyond ” said Dr. Jianwen He, Scientific Director of Mindray IVD.

Information about Mindray

Mindray is a leading developer, manufacturer and provider of medical devices and solutions that provide healthcare professionals worldwide with innovative, life-saving tools for patient monitoring and life support, in vitro diagnostics, medical imaging and orthopedics.

Website:

Photo –

View original content: